Galvain, Thibaut http://orcid.org/0000-0002-0412-249X
Hill, Ruaraidh
Donegan, Sarah
Lisboa, Paulo
Lip, Gregory Y. H.
Czanner, Gabriela
Funding for this research was provided by:
Johnson and Johnson
Article History
Accepted: 17 August 2022
First Online: 19 September 2022
Declarations
:
: TG’s PhD education program is funded by Johnson and Johnson Medical. The funder was not involved in the research, nor in any decisions taken by the authors.
: TG is an employee of Johnson and Johnson Medical. RH declares a financial, non-personal, non-specific interest, having delivered educational workshops on health economics, medicines management and HTA for cancer specialists supported by unrestricted sponsorship by the pharmaceutical industry and an industry association (March 2019). No fees received personally. Not specific to the topic of the review. GYHL has served as a consultant for Bayer/Janssen, Bristol Myers Squibb (BMS)/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo and as a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim and Daiichi-Sankyo. The other authors report no competing interests (SD, PL and GC).
: Not applicable.
: Not applicable.
: Not applicable.
: Template data collection form, data extracted, analytical code and any other study documents will be available from the corresponding author on reasonable request.
: Analytical code will be available from the corresponding author on reasonable request.
: Conceptualization: GYHL, PL, GC, SD, RH and TG; methodology: GYHL, PL, GC, SD, RH and TG; formal analysis: GC and TG; investigation: GYHL, PL, GC, SD, RH and TG; data curation: GC and TG; writing original draft: TG; writing review and editing: GYHL, PL, GC, SD, RH and TG; visualization: TG; final approval: GYHL, PL, GC, SD, RH and TG. All authors read and approved the final version of the manuscript.